Cellumen, MTPC to Develop Biomarker Panels for Early-Stage Drug Tox Screens | GenomeWeb
Cellumen this week announced an agreement with Japan’s Mitsubishi Tanabe Pharma Corporation to develop biomarker panels to identify toxicity early in the drug-development process.
This agreement marks Cellumen’s first play in the Asian market, but a company official said “there will be more to follow.” He did not elaborate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.